Ignite Creation Date:
2024-05-06 @ 3:32 PM
Last Modification Date:
2024-10-26 @ 1:51 PM
Study NCT ID:
NCT04667793
Status:
RECRUITING
Last Update Posted:
2023-04-04
First Post:
2020-12-05
Brief Title:
Clinical Study of Neoadjuvant PD-1 Antibody Toripalimab Plus Chemotherapy for Locally Advanced Thymic Epithelial Tumor
Sponsor:
Shanghai Pulmonary Hospital Shanghai China
Organization:
Shanghai Pulmonary Hospital Shanghai China
Study Overview
Official Title:
Clinical Study of Neoadjuvant PD-1 Antibody Toripalimab Plus Chemotherapy for Locally Advanced Thymic Epithelial Tumor
Status:
RECRUITING
Status Verified Date:
2023-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a phase II single-arm open-label study to evaluate the efficacy and safety of neoadjuvant Toripalimab chemotherapy followed by radical surgery as first-line treatment in patients with locally advanced thymic epithelial tumor
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None